Search

Your search keyword '"Kwon, Eugene D."' showing total 735 results
Start Over Author "Kwon, Eugene D."
735 results on '"Kwon, Eugene D."'

8. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies

Author

Mahmoud, Ahmed M., primary, Moustafa, Amr, additional, Day, Carter, additional, Ahmed, Mohamed E., additional, Zeina, Wael, additional, Marzouk, Usama M., additional, Basourakos, Spyridon, additional, Haloi, Rimki, additional, Mahon, Mindie, additional, Muniz, Miguel, additional, Childs, Daniel S., additional, Orme, Jacob J., additional, Riaz, Irbaz Bin, additional, Kendi, A. Tuba, additional, Stish, Bradley J., additional, Davis, Brian J., additional, Kwon, Eugene D., additional, and Andrews, Jack R., additional

Published
2024
Full Text
View/download PDF

11. Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients

Author

Dasari, Surendra, primary, McCarthy, Michael R., additional, Wojcik, Antonina A., additional, Pitel, Beth A., additional, Samaddar, Arpan, additional, Tekin, Burak, additional, Whaley, Rumeal D., additional, Raghunathan, Aditya, additional, Hernandez, Loren Herrera, additional, Jimenez, Rafael E., additional, Stish, Brad J., additional, Thompson, R. Houston, additional, Leibovich, Bradley C., additional, Boorjian, Stephen A., additional, Jeffrey Karnes, R., additional, Childs, Daniel S., additional, Quevedo, J. Fernando, additional, Kwon, Eugene D., additional, Pagliaro, Lance C., additional, Costello, Brian A., additional, Halling, Kevin C., additional, Cheville, John C., additional, Kipp, Benjamin R., additional, and Gupta, Sounak, additional

Published
2024
Full Text
View/download PDF

13. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer

Author

Deek, Matthew P., Taparra, Kekoa, Dao, Dyda, Chan, Luanna, Phillips, Ryan, Gao, Robert W., Kwon, Eugene D., Deville, Curtiland, Song, Daniel Y., Greco, Stephen, Carducci, Michael A., Eisenberger, Mario, DeWeese, Theodore L., Denmeade, Samuel, Pienta, Kenneth, Paller, Channing J., Antonarakis, Emmanuel S., Olivier, Kenneth R., Park, Sean S., Stish, Bradley J., and Tran, Phuoc T.

Published
2021
Full Text
View/download PDF

14. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies.

Author

Mahmoud, Ahmed M., Moustafa, Amr, Day, Carter, Ahmed, Mohamed E., Zeina, Wael, Marzouk, Usama M., Basourakos, Spyridon, Haloi, Rimki, Mahon, Mindie, Muniz, Miguel, Childs, Daniel S., Orme, Jacob J., Riaz, Irbaz Bin, Kendi, A. Tuba, Stish, Bradley J., Davis, Brian J., Kwon, Eugene D., and Andrews, Jack R.

Subjects
TREATMENT of lung tumors, PROSTATE tumors treatment, DIAGNOSTIC imaging, ANTINEOPLASTIC agents, PROSTATE tumors, CHEMORADIOTHERAPY, METASTASIS, LUNG tumors, DISEASE progression
Abstract

Simple Summary: In our paper, we examine various facets of prostate cancer lung metastasis. We explore their clinical manifestations, such as respiratory symptoms and potential complications. Diagnostic modalities, including imaging techniques and biomarker analysis, are scrutinized for accurate identification. Treatment strategies, encompassing surgery, radiation therapy, chemotherapy, and targeted therapies, are discussed for their efficacy. Survival outcomes are assessed to gauge the effectiveness of different interventions. Through comprehensive analysis, we aim to provide insights into managing prostate cancer lung metastasis and enhancing patient care and outcomes. Prostate cancer lung metastasis represents a clinical conundrum due to its implications for advanced disease progression and the complexities it introduces in treatment planning. As the disease progresses to distant sites such as the lung, the clinical management becomes increasingly intricate, requiring tailored therapeutic strategies to address the unique characteristics of metastatic lesions. This review seeks to synthesize the current state of knowledge surrounding prostate cancer metastasis to the lung, shedding light on the diverse array of clinical presentations encountered, ranging from subtle radiological findings to overt symptomatic manifestations. By examining the diagnostic modalities utilized in identifying this metastasis, including advanced imaging techniques and histopathological analyses, this review aims to provide insights into the diagnostic landscape and the challenges associated with accurately characterizing lung metastatic lesions in prostate cancer patients. Moreover, this review delves into the nuances of therapeutic interventions employed in managing prostate cancer lung metastasis, encompassing systemic treatments such as hormonal therapies and chemotherapy, as well as metastasis-directed therapies including surgery and radiotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer

Author

Ahmed, Mohamed E., primary, Lee, Matthew S., additional, Mahmoud, Ahmed M., additional, Joshi, Vidhu B., additional, Gopalakrishna, Ajay, additional, Bole, Raevti, additional, Haloi, Rimki, additional, Kendi, A. Tuba, additional, Bold, Michael S., additional, Bryce, Alan H., additional, Karnes, Robert Jeffrey, additional, Kwon, Eugene D., additional, Childs, Daniel S., additional, and Andrews, Jack R., additional

Published
2023
Full Text
View/download PDF

18. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis

Author

Mahmoud, Ahmed M., primary, Childs, Daniel S., additional, Ahmed, Mohamed E., additional, Tuba Kendi, A., additional, Johnson, Geoffrey B., additional, Orme, Jacob J., additional, Stish, Bradley J., additional, Phillips, Ryan M., additional, Park, Sean S., additional, Davis, Brian J., additional, Andrews, Jack R., additional, and Kwon, Eugene D., additional

Published
2023
Full Text
View/download PDF

19. Low PSA radiographic disease progression on C11‐choline PET

Author

Mahmoud, Ahmed M., primary, Ahmed, Mohamed E., additional, Kendi, A. Tuba, additional, Thorpe, Matthew, additional, Johnson, Geoffrey B., additional, Riaz, Irbaz Bin, additional, Orme, Jacob J., additional, Kwon, Eugene D., additional, Andrews, Jack R., additional, and Childs, Daniel S., additional

Published
2023
Full Text
View/download PDF

20. The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

Author

McDermott, David F, Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A, Clark, Joseph I, Sosman, Jeffrey A, Dutcher, Janice P, Logan, Theodore F, Curti, Brendan D, Ernstoff, Marc S, Appleman, Leonard, Wong, Michael KK, Khushalani, Nikhil I, Oleksowicz, Leslie, Vaishampayan, Ulka N, Mier, James W, Panka, David J, Bhatt, Rupal S, Bailey, Alexandra S, Leibovich, Bradley C, Kwon, Eugene D, Kabbinavar, Fairooz F, Belldegrun, Arie S, Figlin, Robert A, Pantuck, Allan J, Regan, Meredith M, and Atkins, Michael B

Subjects
Cancer, Kidney Disease, Rare Diseases, Clinical Research, Prevention, Adult, Aged, Antineoplastic Agents, Carcinoma, Renal Cell, Humans, Interleukin-2, Kidney Neoplasms, Middle Aged, Neoplasm Metastasis, Prognosis, Recombinant Proteins, Risk Factors, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeHigh-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2.Experimental designStandard HD IL2 was administered to prospectively evaluate whether the ORR of patients with mRCC with "good" predictive pathologic features based on an "integrated selection" model [ISM (e.g., clear-cell histology subclassification and carbonic anhydrase-9 (CA-9) IHC staining] was significantly higher than the ORR of a historical, unselected population. Archived tumor was collected for pathologic analysis including tumor programmed death-ligand 1 (PD-L1) expression.ResultsOne hundred and twenty eligible patients were enrolled between June 11 and September 7; 70% were Memorial Sloan Kettering Cancer Center (New York, NY) intermediate risk, 96% had clear cell RCC, and 99% had prior nephrectomy. The independently assessed ORR was 25% (30/120, 95% CI, 17.5%-33.7%, P = 0.0014; 3 complete responses, 27 partial responses) and was higher than a historical ORR. Thirteen patients (11%) remained progression free at 3 years and the median overall survival was 42.8 months. ORR was not statistically different by ISM classification ("good-risk" 23% vs. "poor-risk" 30%; P = 0.39). ORR was positively associated with tumor PD-L1 expression (P = 0.01) by IHC.ConclusionsIn this prospective, biomarker validation study, HD IL2 produced durable remissions and prolonged survival in both "good" and "poor-risk" patients. The proposed ISM was unable to improve the selection criteria. Novel markers (e.g., tumor PD L1 expression) appeared useful, but require independent validation.

Published
2015

33. Data from PD-1 Restrains Radiotherapy-Induced Abscopal Effect

Author

Park, Sean S., primary, Dong, Haidong, primary, Liu, Xin, primary, Harrington, Susan M., primary, Krco, Christopher J., primary, Grams, Michael P., primary, Mansfield, Aaron S., primary, Furutani, Keith M., primary, Olivier, Kenneth R., primary, and Kwon, Eugene D., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

Author

Zhang, Henan, primary, Orme, Jacob J., primary, Abraha, Feven, primary, Stish, B.J., primary, Lowe, Val J., primary, Lucien, Fabrice, primary, Tryggestad, Erik J., primary, Bold, Michael S., primary, Pagliaro, Lance C., primary, Choo, C. Richard, primary, Brinkmann, Debra H., primary, Iott, Matthew J., primary, Davis, Brian J., primary, Quevedo, J. Fernando, primary, Harmsen, William S., primary, Costello, Brian A., primary, Johnson, Geoffrey B., primary, Nathan, Mark A., primary, Olivier, Kenneth R., primary, Pisansky, Thomas M., primary, Kwon, Eugene D., primary, Dong, Haidong, primary, and Park, Sean S., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

Author

Zhang, Henan, primary, Orme, Jacob J., primary, Abraha, Feven, primary, Stish, B.J., primary, Lowe, Val J., primary, Lucien, Fabrice, primary, Tryggestad, Erik J., primary, Bold, Michael S., primary, Pagliaro, Lance C., primary, Choo, C. Richard, primary, Brinkmann, Debra H., primary, Iott, Matthew J., primary, Davis, Brian J., primary, Quevedo, J. Fernando, primary, Harmsen, William S., primary, Costello, Brian A., primary, Johnson, Geoffrey B., primary, Nathan, Mark A., primary, Olivier, Kenneth R., primary, Pisansky, Thomas M., primary, Kwon, Eugene D., primary, Dong, Haidong, primary, and Park, Sean S., primary

Published
2023
Full Text
View/download PDF

44. Legend for Supplemental Figure 2legend from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma

Author

Gustafson, Michael P., primary, Lin, Yi, primary, Bleeker, Jonathan S., primary, Warad, Deepti, primary, Tollefson, Matthew K., primary, Crispen, Paul L., primary, Bulur, Peggy A., primary, Harrington, Susan M., primary, Laborde, Rebecca R., primary, Gastineau, Dennis A., primary, Leibovich, Bradley C., primary, Cheville, John C., primary, Kwon, Eugene D., primary, and Dietz, Allan B., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 3 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

Author

Zhang, Henan, primary, Orme, Jacob J., primary, Abraha, Feven, primary, Stish, B.J., primary, Lowe, Val J., primary, Lucien, Fabrice, primary, Tryggestad, Erik J., primary, Bold, Michael S., primary, Pagliaro, Lance C., primary, Choo, C. Richard, primary, Brinkmann, Debra H., primary, Iott, Matthew J., primary, Davis, Brian J., primary, Quevedo, J. Fernando, primary, Harmsen, William S., primary, Costello, Brian A., primary, Johnson, Geoffrey B., primary, Nathan, Mark A., primary, Olivier, Kenneth R., primary, Pisansky, Thomas M., primary, Kwon, Eugene D., primary, Dong, Haidong, primary, and Park, Sean S., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 2 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

Author

Zhang, Henan, primary, Orme, Jacob J., primary, Abraha, Feven, primary, Stish, B.J., primary, Lowe, Val J., primary, Lucien, Fabrice, primary, Tryggestad, Erik J., primary, Bold, Michael S., primary, Pagliaro, Lance C., primary, Choo, C. Richard, primary, Brinkmann, Debra H., primary, Iott, Matthew J., primary, Davis, Brian J., primary, Quevedo, J. Fernando, primary, Harmsen, William S., primary, Costello, Brian A., primary, Johnson, Geoffrey B., primary, Nathan, Mark A., primary, Olivier, Kenneth R., primary, Pisansky, Thomas M., primary, Kwon, Eugene D., primary, Dong, Haidong, primary, and Park, Sean S., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figures 1-6 from B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy

Author

Roth, Timothy J., primary, Sheinin, Yuri, primary, Lohse, Christine M., primary, Kuntz, Susan M., primary, Frigola, Xavier, primary, Inman, Brant A., primary, Krambeck, Amy E., primary, Mckenney, Maureen E., primary, Karnes, R. Jeffrey, primary, Blute, Michael L., primary, Cheville, John C., primary, Sebo, Thomas J., primary, and Kwon, Eugene D., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results